Skip to content

Study · Randomized controlled trial · n = 56 · 2004

2 results

Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery.

Levin RL, Degrange MA, Bruno GF, Del Mazo CD, Taborda DJ, Griotti JJ, Boullon FJ

The Annals of thoracic surgery1 Feb 2004Cited by 191 (Europe PMC)

PMID14759425 (opens in a new tab)DOI10.1016/s0003-4975(03)01510-8 (opens in a new tab)PepBankPUB-14759425
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In patients with postoperative vasoplegia, morbidity and mortality reductions were reported with methylene blue (0%) versus placebo (21.4%).

    In plain wordsIn patients with vasoplegia after cardiac surgery, morbidity and mortality were lower with methylene blue (0%) than with placebo (21.4%).

    Peptide
    Methylene blue
    Outcome
    DecreaseMorbidity and mortality
    Study

    n = 56

    Comparator
    Placebo
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    1.5 mg/Kg · intravenousAs given in this study (human).

    Measurements

    Morbidity and mortality
    0%
    methylene blue
    Morbidity and mortality
    21.4%
    control (placebo), 6 of 28 patients
    Patients in control group
    6 patients
    control (placebo), 6 of 28 patients

    Source sentences

    Summary
    Those treated with methylene blue showed morbidity and mortality reductions (0% versus 21.4% or 6 of 28 patients; p value = 0.01).
    2 context sentences
    Summary · context
    Cardiac surgery patients were consecutively included.
    Summary · context
    Those with vasoplegia were randomized to receive 1.5 mg/Kg of methylene blue or a placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with postoperative vasoplegia, methylene blue shortened the syndrome versus placebo, lasting less than 6 hours in all treated patients versus more than 48 hours in 8 control patients.

    In plain wordsIn cardiac surgery patients with vasoplegia, the syndrome lasted less than 6 hours with methylene blue and more than 48 hours in 8 placebo patients.

    Peptide
    Methylene blue
    Outcome
    DecreaseVasoplegic syndrome duration
    Study

    n = 56

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    1.5 mg/Kg · intravenousAs given in this study (human).

    Measurements

    Duration of vasoplegic syndrome
    < 6 hours
    methylene blue, all patients
    Duration of vasoplegic syndrome
    > 48 hours
    control group, 8 patients
    Control patients with duration >48 hours
    8 patients
    control group

    Source sentences

    Summary
    The duration of the vasoplegic syndrome was shorter in those patients treated with the drug, lasting less than 6 hours in all patients.
    Summary
    Patients in the control group showed a slower recovery, lasting more than 48 hours in 8 patients (p value = 0.0007).
    2 context sentences
    Summary · context
    Cardiac surgery patients were consecutively included.
    Summary · context
    Those with vasoplegia were randomized to receive 1.5 mg/Kg of methylene blue or a placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 not yet recruiting · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase 2/3NCT06306001

Intravenous Methylene Blue for Treating Refractory Neonatal Septic Shock

Post Graduate Institute of Medical Education and Research, Chandigarhn = 130est. 15 Mar 2024 to est. Feb 2027

Neonatal Sepsis · Shock, Septic

Trial pageClinicalTrials.govUpdated 12 Mar 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.